Montelukast PowerPoint Template 2

Montelukast PPT: Medical PowerPoint Template

• The Montelukast PPT template is an animated medical PowerPoint template that will help you realize the full potential of your presentation.
• The RxSlides animated template includes medical animations and infographics that will attract your audience.
• You can use our demonstrated infographics to give your audience a dynamic and appealing Montelukast presentation.

Montelukast PPT Template Content:

• Cover slides to start your Montelukast PPT presentation.

Description

• Montelukast is a leukotriene inhibitor drug used for the treatment of respiratory diseases.

• A fully editable illustration shows the pharmacological structure of Montelukast to help you explain the structure very well.
• The market distribution of the drug is shown in charts with changeable percentages according to your data to help you show the market distribution more clearly.
• The drug is available in the market under the brand name Singulair, produced by Merck.

Dosage Forms and Strengths

• Tablet 10mg
• tablet, chewable tablet 4 mg, 5 mg
• oral granules, 4mg/packet(2)

Montelukast indications

• Montelukast’s most common indications are explained with medical icons in the Montelukast PPT template, including prophylaxis and chronic treatment of asthma, acute prevention of exercise-induced bronchoconstriction (EIB), seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).

Montelukast-associated conditions

• The Montelukast-associated conditions are visualized with animated illustrations that show mild to moderate obstructive sleep apnea, aspirin-induced asthma, atopic dermatitis and chronic urticaria or chronic idiopathic urticaria.

Montelukast black box warning

• FDA (Food and Drug Administration) is requiring a Boxed Warning stating that serious mental health side effects that may include suicidal thoughts or actions have been reported in patients taking asthma and allergy medicine Montelukast (Singulair)
• Contraindications and precautions are explained with visuals illustrating aspirin sensitivity, concomitant corticosteroid use, acute asthma, phenylketonuria, eosinophilic conditions and neuropsychiatric events.

Montelukast pharmacodynamics

• Montelukast’s pharmacodynamics animation shows how montelukast decreases nasal congestion and inflammation associated with allergic rhinitis.
• Montelukast decreases the narrowing and obstruction of the airways in obstructive lung diseases such as asthma; it binds to cysteinyl leukotriene receptor type-1 and elicits substantial blockage of LTD4.
• Montelukast can cause bronchodilation as soon as within 2 hours of oral administration.

Montelukast mechanism of action PPT slides

• The Montelukast mechanism of action is also explained with animations and illustrations in the Montelukast PPT showing immunologic activation during which inflammatory stimuli are produced.
• Arachidonic acid is liberated from the membrane phospholipids with the help of the phospholipase A2 enzyme; arachidonic acid is rapidly oxidized by the lipoxygenase (LOX) pathway to form leukotrienes.
• After releasing leukotrienes, the eicosanoids bind to cysteinyl leukotriene (CysLT) receptors in the human airway, causing airway swelling and obstruction.
• As illustrated in Montelukast PPT slides, Montelukast binds with high affinity and selectivity to the CysLT1 receptor and inhibits the physiologic actions of LTD4; it prevents leukotrienes from binding to CysLT1 receptors.

Montelukast absorption

• Absorption, mean peak montelukast plasma concentration, oral bioavailability and protein binding are visualized and explained with animated icons and illustrations.

Montelukast metabolism

• Drug metabolism is also presented with animations that show metabolism by the cytochrome P450 3A4, 2C8 and 2C9 isoenzymes.
• CYP2C8 enzymes play a significant role in the metabolism of the drug, oxidation, or removing electrons from the compound and producing montelukast byproducts including M1, M2a, M2b, M5a, M5b, M6a, M6b, montelukast sulfoxide, 21-Hydroxymontelukast, 21(s)Hydroxy montelukast, Montelukast 1, 2-Diol.

Montelukast elimination

• The route of elimination, which is exclusive, is drug excretion in the bile and into the feces.
• The half-life and the plasma clearance are all explained using visually appealing animated infographics and illustrations, which are also editable according to your data.

Montelukast adverse effects

• The adverse effects are explained with visuals and the severe, moderate and mild ones are mentioned using animated icons and illustrations.

Montelukast toxicity

• Finally, the drug forms, the toxicity and the maximum dosage of the drug are visualized and illustrated.

RxSlides visuals of Montelukast PowerPoint presentation

• Set of PowerPoint icons and illustrations related to Montelukast, which will help you customize the content of this 100% editable presentation according to your content and audience interest.